Stroke RSS

Filtered By:
Source: International Journal of Stroke
Drug: Pradaxa

This page shows you your search results in order of date.

Order by Relevance | Date

Total 8 results found since Jan 2013.

Design of Randomized, double‐blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE‐SPECT ESUS)
DiscussionAcetylsalicylic acid is the most common antithrombotic given to patients with embolic strokes of undetermined source to reduce recurrence risk. This trial will determine whether anticoagulation with dabigatran is more effective than acetylsalicylic acid, and acceptably safe.
Source: International Journal of Stroke - September 30, 2015 Category: Neurology Authors: Hans‐Christoph Diener, J. Donald Easton, Christopher B. Granger, Lisa Cronin, Christine Duffy, Daniel Cotton, Martina Brueckmann, Ralph L. Sacco, Tags: Protocol Source Type: research

Intravenous thrombolysis in wake‐up stroke in a 92‐year‐old patient under dabigatran
Source: International Journal of Stroke - September 24, 2015 Category: Neurology Authors: Alessio Pieroni, Maria Luisa Capuana, Anne Falcou, Danilo Toni Tags: Letter to the editor Source Type: research

Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients
ConclusionsWe report the largest series of cerebral vein thrombosis patients treated with dabigatran. Clinical outcome was excellent in most patients and not different from other studies. Dabigatran could possibly be considered an alternative to warfarin; nevertheless, further prospective assessment with randomized controlled studies is warranted.
Source: International Journal of Stroke - February 1, 2015 Category: Neurology Authors: Marcelo D. Mendonça, Raquel Barbosa, Vera Cruz‐e‐Silva, Sofia Calado, Miguel Viana‐Baptista Tags: Research Source Type: research

Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: The SAMURAI‐NVAF Study
ConclusionsWarfarin use at acute hospital discharge was still common in the initial years after approval of nonvitamin K antagonist oral anticoagulants, although nonvitamin K antagonist oral anticoagulant users increased gradually. The index stroke was milder and ischemia‐risk indices were lower in nonvitamin K antagonist oral anticoagulant users than in warfarin users. Early initiation of nonvitamin K antagonist oral anticoagulants seemed safe.
Source: International Journal of Stroke - January 12, 2015 Category: Neurology Authors: Kazunori Toyoda, Shoji Arihiro, Kenichi Todo, Hiroshi Yamagami, Kazumi Kimura, Eisuke Furui, Tadashi Terasaki, Yoshiaki Shiokawa, Kenji Kamiyama, Shunya Takizawa, Satoshi Okuda, Yasushi Okada, Tomoaki Kameda, Yoshinari Nagakane, Yasuhiro Hasegawa, Hiroshi Tags: Research Source Type: research

Management of acute stroke in patients taking novel oral anticoagulants
Each year, 1·0–2·0% of individuals with atrial fibrillation and 0·1–0·2% of those with venous thromboembolism who are receiving one of the novel oral anticoagulants (dabigatran, rivaroxaban, or apixaban) can be expected to experience an acute ischemic stroke. Additionally, 0·2–0·5% of individuals with atrial fibrillation who are receiving one of the novel oral anticoagulants can be expected to experience an intracranial hemorrhage. This opinion piece addresses the current literature and offers practical approaches to the management of patients receiving novel oral anticoagulants who present with an ischemic or ...
Source: International Journal of Stroke - June 1, 2014 Category: Neurology Authors: Graeme J. Hankey, Bo Norrving, Werner Hacke, Thorsten Steiner Tags: Review Source Type: research